GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
R

Replimune Group REPL · USD

Health Care · US listing · 🇺🇸 United States

Compare

22.26

+2.96%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Net income

−$313.9m

FY2017FY2026

Free cash flow

−$284.6m

FY2017FY2026

Shareholders' equity

$166.2m

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Gross profit—−$3.5m−$2.7m−$2.4m−$4.6m−$4.1m−$1.8m−$148,000−$109,000−$122,000
Research and development$221.2m$189.4m$175.0m$126.5m$80.6m$57.5m$38.8m$22.2m$13.5m$6.9m
Operating income−$319.9m−$261.6m−$234.8m−$177.1m−$121.5m−$80.6m−$56.2m−$30.9m−$19.2m−$9.6m
Net income−$313.9m−$247.3m−$215.8m−$174.3m−$118.0m−$80.9m−$52.6m−$30.8m−$19.7m−$7.7m
Diluted earnings per share-3.24-2.68-2.58-2.62-2.04-1.55-1.07-0.88-0.62-0.25

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$332.4m$551.3m$487.7m$646.6m$461.2m$543.1m$234.1m$154.3m$65.2m$22.8m
Cash and short-term investments$268.9m$483.8m$420.7m$583.4m$395.7m$476.3m$168.6m$134.8m$61.6m$20.6m
Total liabilities$166.2m$135.5m$113.2m$91.3m$50.0m$44.4m$50.4m$16.5m$93.2m$34.3m
Debt$87.3m$71.9m$70.9m$55.3m$27.0m$27.2m$37.2m$6.6m——
Shareholders' equity$166.2m$415.8m$374.5m$555.3m$411.2m$498.7m$183.7m$137.9m−$28.1m−$11.5m
Shares outstanding97m92m83m67m58m52m49m35m32m31m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−$280.3m−$192.3m−$185.5m−$128.1m−$82.2m−$61.4m−$60.6m−$25.4m−$16.0m−$7.1m
Capital spending−$4.2m−$6.7m−$5.7m−$2.3m−$2.3m−$2.4m−$6.5m−$2.6m−$136,000−$238,000
Free cash flow−$284.6m−$198.9m−$191.1m−$130.3m−$84.5m−$63.8m−$67.1m−$28.0m−$16.1m−$7.3m
Dividends paid—————−$91.7m−$28.1m———

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue—————$1.5m——
Gross profit——−$1.6m−$1.6m−$1.7m−$848,000−$1.0m−$900,000
Operating income−$68.2m−$73.3m−$71.9m−$84.3m−$90.4m−$79.9m−$66.0m−$58.9m
Net income−$69.8m−$73.2m−$70.9m−$83.1m−$86.7m−$74.1m−$66.3m−$53.1m
Diluted earnings per share-0.72-0.76-0.77-0.90-0.94-0.80-0.79-0.64
Cash from operations−$75.0m−$56.0m−$65.0m−$81.0m−$77.0m−$53.0m−$50.0m−$38.0m
Capital spending———−$1.0m−$2.0m−$1.0m−$1.0m−$2.0m
Free cash flow———−$82.0m−$79.0m−$54.0m−$51.0m−$40.0m
Total assets$252.4m$332.4m$333.6m$389.4m$469.5m$551.3m$603.6m$498.2m
Cash and short-term investments$195.3m$268.9m$269.1m$323.6m$403.3m$483.8m$536.5m$432.1m
Debt$4.0m$87.3m$51.7m$51.3m$50.8m$50.4m$49.9m$49.5m
Shareholders' equity$105.6m$166.2m$210.5m$263.3m$336.7m$415.8m$482.4m$381.5m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income21.8%31.7%—
Net income21.7%31.2%—

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Price to earnings-6.4-1.3-0.2-0.2-0.4-0.5-1.0-0.4-0.4

Share price return

Finished calendar years

20252024202320222021202020192018
Return503%52%-45%-5%-34%171%8%-10%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.